Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Buy
61
KALV Quote, Financials, Valuation and Earnings
Last price:
$16.41
Seasonality move
:
6.97%
Day range:
$14.30 - $16.80
52-week range:
$7.30 - $17.28
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
50.86x
P/B ratio:
43.59x
Volume:
6.4M
Avg. volume:
1.4M
1-year change:
50.67%
Market cap:
$741M
Revenue:
--
EPS (TTM):
-$4.01
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
KALV
KalVista Pharmaceuticals, Inc.
|
$4.2M | -$1.04 | -- | -18.07% | $31.00 |
|
BYSI
BeyondSpring, Inc.
|
-- | -- | -- | -- | -- |
|
IOVA
Iovance Biotherapeutics, Inc.
|
$72.8M | -$0.26 | 11.66% | -35.2% | $8.25 |
|
RVMD
Revolution Medicines, Inc.
|
$1.5M | -$1.41 | -53.35% | -42.67% | $81.15 |
|
TVTX
Travere Therapeutics, Inc.
|
$106.1M | -$0.09 | 91.27% | -87.94% | $41.5000 |
|
XBIO
Xenetic Biosciences, Inc.
|
$631.9K | -- | 6.75% | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
KALV
KalVista Pharmaceuticals, Inc.
|
$14.66 | $31.00 | $741M | -- | $0.00 | 0% | 50.86x |
|
BYSI
BeyondSpring, Inc.
|
$1.90 | -- | $76.6M | 25.86x | $0.00 | 0% | 29.97x |
|
IOVA
Iovance Biotherapeutics, Inc.
|
$2.21 | $8.25 | $877.3M | -- | $0.00 | 0% | 2.93x |
|
RVMD
Revolution Medicines, Inc.
|
$77.69 | $81.15 | $15B | -- | $0.00 | 0% | -- |
|
TVTX
Travere Therapeutics, Inc.
|
$34.8500 | $41.5000 | $3.1B | -- | $0.00 | 0% | 7.26x |
|
XBIO
Xenetic Biosciences, Inc.
|
$2.42 | -- | $5.5M | -- | $0.00 | 0% | 1.31x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
KALV
KalVista Pharmaceuticals, Inc.
|
94.33% | -1.515 | 45.9% | 6.99x |
|
BYSI
BeyondSpring, Inc.
|
-1.29% | 2.241 | 0.48% | 0.98x |
|
IOVA
Iovance Biotherapeutics, Inc.
|
6.96% | -0.206 | 6.28% | 2.92x |
|
RVMD
Revolution Medicines, Inc.
|
9.03% | 1.466 | 1.79% | 7.86x |
|
TVTX
Travere Therapeutics, Inc.
|
81.76% | 1.077 | 15.42% | 2.50x |
|
XBIO
Xenetic Biosciences, Inc.
|
-- | 3.604 | -- | 3.71x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
KALV
KalVista Pharmaceuticals, Inc.
|
$12.5M | -$46.1M | -97.51% | -243.25% | -336.33% | -$54.8M |
|
BYSI
BeyondSpring, Inc.
|
-$21K | -$1.8M | -- | -- | -- | -$4.3M |
|
IOVA
Iovance Biotherapeutics, Inc.
|
$20M | -$89.8M | -50.35% | -54.43% | -133.06% | -$89.5M |
|
RVMD
Revolution Medicines, Inc.
|
-$4.3M | -$315.3M | -47.95% | -51.27% | -- | -$210.7M |
|
TVTX
Travere Therapeutics, Inc.
|
$147.5M | $24.9M | -21.07% | -263.9% | 15.12% | -$871K |
|
XBIO
Xenetic Biosciences, Inc.
|
-- | -$544.7K | -59.39% | -59.39% | -53.04% | -$658.2K |
KalVista Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns KALV or BYSI?
BeyondSpring, Inc. has a net margin of -361.39% compared to KalVista Pharmaceuticals, Inc.'s net margin of --. KalVista Pharmaceuticals, Inc.'s return on equity of -243.25% beat BeyondSpring, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital KALVKalVista Pharmaceuticals, Inc.91% -$0.92 $299.6M BYSIBeyondSpring, Inc.-- -$0.04 -$19.4M -
What do Analysts Say About KALV or BYSI?
KalVista Pharmaceuticals, Inc. has a consensus price target of $31.00, signalling upside risk potential of 111.46%. On the other hand BeyondSpring, Inc. has an analysts' consensus of -- which suggests that it could fall by -34.21%. Given that KalVista Pharmaceuticals, Inc. has higher upside potential than BeyondSpring, Inc., analysts believe KalVista Pharmaceuticals, Inc. is more attractive than BeyondSpring, Inc..
Company Buy Ratings Hold Ratings Sell Ratings KALVKalVista Pharmaceuticals, Inc.7 0 0 BYSIBeyondSpring, Inc.0 0 0 -
Is KALV or BYSI More Risky?
KalVista Pharmaceuticals, Inc. has a beta of -0.135, which suggesting that the stock is 113.476% less volatile than S&P 500. In comparison BeyondSpring, Inc. has a beta of 0.528, suggesting its less volatile than the S&P 500 by 47.227%.
-
Which is a Better Dividend Stock KALV or BYSI?
KalVista Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BeyondSpring, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. KalVista Pharmaceuticals, Inc. pays -- of its earnings as a dividend. BeyondSpring, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KALV or BYSI?
KalVista Pharmaceuticals, Inc. quarterly revenues are $13.7M, which are larger than BeyondSpring, Inc. quarterly revenues of --. KalVista Pharmaceuticals, Inc.'s net income of -$49.5M is lower than BeyondSpring, Inc.'s net income of -$1.7M. Notably, KalVista Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while BeyondSpring, Inc.'s PE ratio is 25.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for KalVista Pharmaceuticals, Inc. is 50.86x versus 29.97x for BeyondSpring, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KALVKalVista Pharmaceuticals, Inc.50.86x -- $13.7M -$49.5M BYSIBeyondSpring, Inc.29.97x 25.86x -- -$1.7M
-
Which has Higher Returns KALV or IOVA?
Iovance Biotherapeutics, Inc. has a net margin of -361.39% compared to KalVista Pharmaceuticals, Inc.'s net margin of -135.28%. KalVista Pharmaceuticals, Inc.'s return on equity of -243.25% beat Iovance Biotherapeutics, Inc.'s return on equity of -54.43%.
Company Gross Margin Earnings Per Share Invested Capital KALVKalVista Pharmaceuticals, Inc.91% -$0.92 $299.6M IOVAIovance Biotherapeutics, Inc.29.61% -$0.25 $754.8M -
What do Analysts Say About KALV or IOVA?
KalVista Pharmaceuticals, Inc. has a consensus price target of $31.00, signalling upside risk potential of 111.46%. On the other hand Iovance Biotherapeutics, Inc. has an analysts' consensus of $8.25 which suggests that it could grow by 273.3%. Given that Iovance Biotherapeutics, Inc. has higher upside potential than KalVista Pharmaceuticals, Inc., analysts believe Iovance Biotherapeutics, Inc. is more attractive than KalVista Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings KALVKalVista Pharmaceuticals, Inc.7 0 0 IOVAIovance Biotherapeutics, Inc.6 4 1 -
Is KALV or IOVA More Risky?
KalVista Pharmaceuticals, Inc. has a beta of -0.135, which suggesting that the stock is 113.476% less volatile than S&P 500. In comparison Iovance Biotherapeutics, Inc. has a beta of 0.827, suggesting its less volatile than the S&P 500 by 17.288%.
-
Which is a Better Dividend Stock KALV or IOVA?
KalVista Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Iovance Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. KalVista Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Iovance Biotherapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KALV or IOVA?
KalVista Pharmaceuticals, Inc. quarterly revenues are $13.7M, which are smaller than Iovance Biotherapeutics, Inc. quarterly revenues of $67.5M. KalVista Pharmaceuticals, Inc.'s net income of -$49.5M is higher than Iovance Biotherapeutics, Inc.'s net income of -$91.3M. Notably, KalVista Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Iovance Biotherapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for KalVista Pharmaceuticals, Inc. is 50.86x versus 2.93x for Iovance Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KALVKalVista Pharmaceuticals, Inc.50.86x -- $13.7M -$49.5M IOVAIovance Biotherapeutics, Inc.2.93x -- $67.5M -$91.3M
-
Which has Higher Returns KALV or RVMD?
Revolution Medicines, Inc. has a net margin of -361.39% compared to KalVista Pharmaceuticals, Inc.'s net margin of --. KalVista Pharmaceuticals, Inc.'s return on equity of -243.25% beat Revolution Medicines, Inc.'s return on equity of -51.27%.
Company Gross Margin Earnings Per Share Invested Capital KALVKalVista Pharmaceuticals, Inc.91% -$0.92 $299.6M RVMDRevolution Medicines, Inc.-- -$1.61 $1.8B -
What do Analysts Say About KALV or RVMD?
KalVista Pharmaceuticals, Inc. has a consensus price target of $31.00, signalling upside risk potential of 111.46%. On the other hand Revolution Medicines, Inc. has an analysts' consensus of $81.15 which suggests that it could grow by 4.45%. Given that KalVista Pharmaceuticals, Inc. has higher upside potential than Revolution Medicines, Inc., analysts believe KalVista Pharmaceuticals, Inc. is more attractive than Revolution Medicines, Inc..
Company Buy Ratings Hold Ratings Sell Ratings KALVKalVista Pharmaceuticals, Inc.7 0 0 RVMDRevolution Medicines, Inc.17 0 0 -
Is KALV or RVMD More Risky?
KalVista Pharmaceuticals, Inc. has a beta of -0.135, which suggesting that the stock is 113.476% less volatile than S&P 500. In comparison Revolution Medicines, Inc. has a beta of 0.959, suggesting its less volatile than the S&P 500 by 4.08%.
-
Which is a Better Dividend Stock KALV or RVMD?
KalVista Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Revolution Medicines, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. KalVista Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Revolution Medicines, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KALV or RVMD?
KalVista Pharmaceuticals, Inc. quarterly revenues are $13.7M, which are larger than Revolution Medicines, Inc. quarterly revenues of --. KalVista Pharmaceuticals, Inc.'s net income of -$49.5M is higher than Revolution Medicines, Inc.'s net income of -$305.2M. Notably, KalVista Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Revolution Medicines, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for KalVista Pharmaceuticals, Inc. is 50.86x versus -- for Revolution Medicines, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KALVKalVista Pharmaceuticals, Inc.50.86x -- $13.7M -$49.5M RVMDRevolution Medicines, Inc.-- -- -- -$305.2M
-
Which has Higher Returns KALV or TVTX?
Travere Therapeutics, Inc. has a net margin of -361.39% compared to KalVista Pharmaceuticals, Inc.'s net margin of 15.59%. KalVista Pharmaceuticals, Inc.'s return on equity of -243.25% beat Travere Therapeutics, Inc.'s return on equity of -263.9%.
Company Gross Margin Earnings Per Share Invested Capital KALVKalVista Pharmaceuticals, Inc.91% -$0.92 $299.6M TVTXTravere Therapeutics, Inc.89.46% $0.25 $403.3M -
What do Analysts Say About KALV or TVTX?
KalVista Pharmaceuticals, Inc. has a consensus price target of $31.00, signalling upside risk potential of 111.46%. On the other hand Travere Therapeutics, Inc. has an analysts' consensus of $41.5000 which suggests that it could grow by 19.08%. Given that KalVista Pharmaceuticals, Inc. has higher upside potential than Travere Therapeutics, Inc., analysts believe KalVista Pharmaceuticals, Inc. is more attractive than Travere Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings KALVKalVista Pharmaceuticals, Inc.7 0 0 TVTXTravere Therapeutics, Inc.12 2 0 -
Is KALV or TVTX More Risky?
KalVista Pharmaceuticals, Inc. has a beta of -0.135, which suggesting that the stock is 113.476% less volatile than S&P 500. In comparison Travere Therapeutics, Inc. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.435%.
-
Which is a Better Dividend Stock KALV or TVTX?
KalVista Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Travere Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. KalVista Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Travere Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KALV or TVTX?
KalVista Pharmaceuticals, Inc. quarterly revenues are $13.7M, which are smaller than Travere Therapeutics, Inc. quarterly revenues of $164.9M. KalVista Pharmaceuticals, Inc.'s net income of -$49.5M is lower than Travere Therapeutics, Inc.'s net income of $25.7M. Notably, KalVista Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Travere Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for KalVista Pharmaceuticals, Inc. is 50.86x versus 7.26x for Travere Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KALVKalVista Pharmaceuticals, Inc.50.86x -- $13.7M -$49.5M TVTXTravere Therapeutics, Inc.7.26x -- $164.9M $25.7M
-
Which has Higher Returns KALV or XBIO?
Xenetic Biosciences, Inc. has a net margin of -361.39% compared to KalVista Pharmaceuticals, Inc.'s net margin of -49.65%. KalVista Pharmaceuticals, Inc.'s return on equity of -243.25% beat Xenetic Biosciences, Inc.'s return on equity of -59.39%.
Company Gross Margin Earnings Per Share Invested Capital KALVKalVista Pharmaceuticals, Inc.91% -$0.92 $299.6M XBIOXenetic Biosciences, Inc.-- -$0.33 $4M -
What do Analysts Say About KALV or XBIO?
KalVista Pharmaceuticals, Inc. has a consensus price target of $31.00, signalling upside risk potential of 111.46%. On the other hand Xenetic Biosciences, Inc. has an analysts' consensus of -- which suggests that it could grow by 1552.89%. Given that Xenetic Biosciences, Inc. has higher upside potential than KalVista Pharmaceuticals, Inc., analysts believe Xenetic Biosciences, Inc. is more attractive than KalVista Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings KALVKalVista Pharmaceuticals, Inc.7 0 0 XBIOXenetic Biosciences, Inc.0 1 0 -
Is KALV or XBIO More Risky?
KalVista Pharmaceuticals, Inc. has a beta of -0.135, which suggesting that the stock is 113.476% less volatile than S&P 500. In comparison Xenetic Biosciences, Inc. has a beta of 2.398, suggesting its more volatile than the S&P 500 by 139.837%.
-
Which is a Better Dividend Stock KALV or XBIO?
KalVista Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xenetic Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. KalVista Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Xenetic Biosciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KALV or XBIO?
KalVista Pharmaceuticals, Inc. quarterly revenues are $13.7M, which are larger than Xenetic Biosciences, Inc. quarterly revenues of $1M. KalVista Pharmaceuticals, Inc.'s net income of -$49.5M is lower than Xenetic Biosciences, Inc.'s net income of -$509.9K. Notably, KalVista Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Xenetic Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for KalVista Pharmaceuticals, Inc. is 50.86x versus 1.31x for Xenetic Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KALVKalVista Pharmaceuticals, Inc.50.86x -- $13.7M -$49.5M XBIOXenetic Biosciences, Inc.1.31x -- $1M -$509.9K
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
64
Is AAPL Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 38x
Buy
69
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Sell
47
PSTG alert for Dec 4
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
41
SMX alert for Dec 4
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
43
HY alert for Dec 4
Hyster-Yale, Inc. [HY] is up 1.92% over the past day.
